1. Amadori D, Nanni O, Marangolo M et al: Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with node-negative rapidly proliferating breast cancer. A randomized multicenter study. J Clin Oncol 18: 3125–3134, 2000
2. Baki M, Radó J, Gyergyay F ésmtsai: Tapasztalataink elõrehaladott stádiumú emlõdaganatos betegek Adriblastin (A) és Docetaxel (D) összehasonlító vizsgálata során. Magy Onkol Társ XXII. Nemzeti Kongr Magyar Onkol 41: 300–301, 1997 (in Hungarian)
3. Bonadonna G, Valagussa P: The contribution of medicine to the primary treatment of breast cancer. Cancer Res 48: 2314–2324, 1998
4. Bonneterre, Roche H, Monnier A et al: Taxotere(TXT) versus 5-Fluorouracil + Navelbine (FUN) as second-line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 16:162a, 1997
5. Chan S, Friedrich K, Noel D et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354, 1999